Tapan K Mukherjee1,2,3, Parth Malik4,5, John R Hoidal6,7,8. 1. Division of Respiratory, Critical Care and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA. tapanmu@yahoo.com. 2. Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. tapanmu@yahoo.com. 3. George E. Wahlen Department of Veterans Affairs Medical Center, 500, Foothil Drive, Building#45, Salt Lake City, UT, 84148, USA. tapanmu@yahoo.com. 4. School of Chemical Sciences, Central University of Gujarat (Gandhinagar), Gandhinagar, India. 5. School of Nano Sciences, Central University of Gujarat (Gandhinagar), Gandhinagar, India. 6. Division of Respiratory, Critical Care and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA. 7. Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. 8. George E. Wahlen Department of Veterans Affairs Medical Center, 500, Foothil Drive, Building#45, Salt Lake City, UT, 84148, USA.
Abstract
PURPOSE OF REVIEW: Non-small cell lung cancers (NSCLCs) account for ~ 85% of all lung cancers, and 5-year survival in Europe and the USA is ~ 13-17%. In this review, we focus on the significance of Receptor for Advanced Glycation End products (RAGE) as a diagnostic or post-therapeutic prognostic marker for various forms of NSCLCs. RECENT FINDINGS: The lungs have the highest levels of basal RAGE expression in mammals. The physiologic RAGE in lungs may be involved in adhesion and spreading of AT-1 cells and maintenance of pulmonary homeostasis. However, high level expression of RAGE complicates various diseases including acute lung injury. In NSCLCs, while a number of studies report decreased RAGE expression, inferring a protective role, others suggest that RAGE expression may contribute to NSCLC pathogenesis. Genetic polymorphisms of RAGE are reportedly associated with NSCLC development and complications. RAGE and its polymorphic variants may be useful diagnostic or post-therapeutic prognostic markers of NSCLCs.
PURPOSE OF REVIEW: Non-small cell lung cancers (NSCLCs) account for ~ 85% of all lung cancers, and 5-year survival in Europe and the USA is ~ 13-17%. In this review, we focus on the significance of Receptor for Advanced Glycation End products (RAGE) as a diagnostic or post-therapeutic prognostic marker for various forms of NSCLCs. RECENT FINDINGS: The lungs have the highest levels of basal RAGE expression in mammals. The physiologic RAGE in lungs may be involved in adhesion and spreading of AT-1 cells and maintenance of pulmonary homeostasis. However, high level expression of RAGE complicates various diseases including acute lung injury. In NSCLCs, while a number of studies report decreased RAGE expression, inferring a protective role, others suggest that RAGE expression may contribute to NSCLC pathogenesis. Genetic polymorphisms of RAGE are reportedly associated with NSCLC development and complications. RAGE and its polymorphic variants may be useful diagnostic or post-therapeutic prognostic markers of NSCLCs.
Entities:
Keywords:
Alveolar type 1 (AT-1) epithelial cells; Lung cancer diagnosis and post-therapeutic prognosis; Non-small cell lung cancers (NSCLCs); Receptor for Advanced Glycation End products (RAGE)
Authors: J Brett; A M Schmidt; S D Yan; Y S Zou; E Weidman; D Pinsky; R Nowygrod; M Neeper; C Przysiecki; A Shaw Journal: Am J Pathol Date: 1993-12 Impact factor: 4.307
Authors: Nina Demling; Carsten Ehrhardt; Michael Kasper; Michael Laue; Lilla Knels; Ernst Peter Rieber Journal: Cell Tissue Res Date: 2005-11-29 Impact factor: 5.249
Authors: Hans-Stefan Hofmann; Gesine Hansen; Stefan Burdach; Babett Bartling; Rolf-Edgar Silber; Andreas Simm Journal: Am J Respir Crit Care Med Date: 2004-09-01 Impact factor: 21.405
Authors: Louis J Sparvero; Denise Asafu-Adjei; Rui Kang; Daolin Tang; Neilay Amin; Jaehyun Im; Ronnye Rutledge; Brenda Lin; Andrew A Amoscato; Herbert J Zeh; Michael T Lotze Journal: J Transl Med Date: 2009-03-17 Impact factor: 5.531